Latest Commercialization News

Everest Metals has received $150,000 from the Minerals Research Institute of Western Australia to advance rubidium extraction at its Mt Edon project, aiming to establish Australia’s first commercial rubidium industry and reduce reliance on Chinese supply chains.

Wesfarmers delivered a solid FY25 with revenue rising 3.4% to $45.7 billion and net profit after tax up 14.4%, driven by strong performances in Bunnings and Kmart. The company announced increased dividends and a proposed capital return, while navigating challenges in its lithium business and ongoing cost pressures.

Wesfarmers Limited reported a 14.4% rise in net profit for FY2025, driven by strong retail performances and strategic portfolio moves. The company also announced a fully-franked final dividend and a significant capital management distribution, signaling confidence amid economic headwinds.

United Overseas Australia Ltd reported a robust half-year profit increase of 31.5%, driven by strong property development and hospitality performance, while declaring a new interim dividend.

Biotron Limited reported a significantly reduced net loss of $318,572 for FY2025, bolstered by a $1.27 million capital raise and a $1.81 million R&D tax rebate, as it advances clinical and preclinical antiviral programs.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

N1 Holdings reported a 6.8% revenue increase to $19.69 million for FY25, while net profit fell 21.1% to $855,826. The company advanced AI initiatives and expanded lending capacity, signaling strategic growth despite profit pressures.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Optiscan Imaging Ltd has launched a fully underwritten $17.75 million entitlement offer to fund clinical trials and regulatory clearances for its medical devices, marking a pivotal step in its transition to a commercial medical device manufacturer.

Invion Limited posted a $8.8 million loss for FY25, marking a 56.5% increase, while advancing clinical trials and securing fresh capital. The biotech faces a going concern warning amid ongoing development and funding challenges.